Alto Neuroscience (ANRO) Income towards Parent Company (2023 - 2026)

Alto Neuroscience has reported Income towards Parent Company for 4 years, with the latest figure at -$26.1 million in Q1 2026.

• Quarterly Income towards Parent Company fell 64.82% year-over-year to -$26.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.3 billion (down 3479.2% YoY) and the FY2025 annual result came in at -$111.9 million, down 15.18% from the prior year.
• Income towards Parent Company slipped to -$26.1 million in Q1 2026 per ANRO's latest filing, from -$15.3 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$7.3 million in Q1 2023 and troughed at -$1.9 billion in Q3 2025.
• A 4-year average of -$183.6 million and a median of -$15.3 million in 2025 frame the typical range for Income towards Parent Company.
• The widest YoY moves for Income towards Parent Company: up 2.64% in 2025, down 10975.11% in 2025.
• Over 4 years, Income towards Parent Company stood at -$10.9 million in 2023, then plunged by 36.03% to -$14.9 million in 2024, then retreated by 2.64% to -$15.3 million in 2025, then tumbled by 71.25% to -$26.1 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$26.1 million, -$15.3 million, and -$1.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.